SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
  • 2
    Sandler AB, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.
  • 3
    DuBois S, Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer. 2007; 109: 813-819.
  • 4
    Comandone A, Boglione A, Berardengo E, et al; for the Italian Sarcoma Group. Microvessel density (MVD) as a marker of neoangiogenesis: prognostic significance in correlation to grading and stage in adult soft tissue sarcoma (STS) of the extremities. A perspective study. Proc Am Soc Clin Oncol. 2003; 22. Abstract 3303.
  • 5
    West CC, Brown NJ, Mangham DC, Grimer RJ, Reed MWR. Microvessel density does not predict outcome in high grade soft tissue sarcoma. Eur J Surg Oncol. 2005; 31: 1198-1205.
  • 6
    Saenz NC, Heslin MJ, Adsay V, et al. Neovascularity and clinical outcome in high grade extremity soft tissue sarcoma. Ann Surg Oncol. 1998; 5: 48-53.
  • 7
    Yudoh K, Manamori M, Ohmori K, Yasudah T, Aoki M, Kimura T. Concentration of vascular endothelial growth factor in tumour tissue as a prognostic factor of soft tissue sarcoma. Br J Cancer. 2001; 84: 1610-1615.
  • 8
    Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrinol Rev. 2004; 25: 581-611.
  • 9
    Potti A, Ganti AK, Tendulkar K, et al. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J Cancer Res Clin Oncol. 2004; 130: 52-56.
  • 10
    Chao C, Al-Saleem T, Brooks J, et al. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol. 2001; 8: 260-267.
  • 11
    Iyoda A, Hiroshima K, Baba M, Fujisawa T, Yusa T, Ohwada H. Expression of vascular endothelial growth factor in thoracic sarcomas. Ann Thorac Surg. 2001; 71: 1635-1639.
  • 12
    Graeven U, Andre N, Achilles E, Zornig C, Schmiegel W. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft tissue sarcoma. J Cancer Res Clin Oncol. 1999; 125: 577-581.
  • 13
    Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357: 2666-2676.
  • 14
    D'Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft tissue sarcomas. J Clin Oncol. 2005; 23: 7135-7142.
  • 15
    Haddad PA, Skubitz KM. Combination of bevacizumab (A) and pegylated-doxorubicin (PLD) (PLD-A) in sarcoma (SAR). 2006 ASCO Annual Meeting Proceedings, part 1 [abstract]. J Clin Oncol. 2006; 24( June 20 suppl): 18S. Abstract 9556.
  • 16
    Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002; 20: 2824-2831.
  • 17
    Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared to gemcitabine alone in patients with soft tissue sarcoma. J Clin Oncol. 2007; 25: 2755-2763.
  • 18
    Verschraegen CF, Fekrazad HM, Rabinowitz I, et al. Phase I/II study of docetaxel (D), gemcitabine (G), and bevacizumab (B) in patients (pts) with advanced or recurrent soft tissue sarcoma (STS). 2007 ASCO Annual Meeting Proceedings, part 1 [abstract]. J Clin Oncol. 2008; 25( 18S; June 20 suppl). Abstract 10056.
  • 19
    Vigil CE, Chiappori AA, Williams CA, et al. Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas. J Clin Oncol. 2008; 26( May 20 suppl). Abstract 10535.
  • 20
    Keohan ML, Morgan JA, D'Adamo DR, et al. Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: results of a phase II trial [abstract]. J Clin Oncol. 2008; 26( May 20 suppl). Abstract 10533.
  • 21
    Maki RG, Keohan ML, Undevia SD, et al; Sorafenib Sarcoma Study Group. Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study 7060 [abstract]. J Clin Oncol. 2008; 26( May 20 suppl). Abstract 10531.
  • 22
    Ryan CW, von Mehren M, Rankin CJ, et al. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcoma (STS): SWOG 0505 [abstract]. J Clin Oncol. 2008; 26( May 20 suppl). Abstract 10532,
  • 23
    Jiang BH, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 1997; 57: 5328-5335.
  • 24
    Schenone S, Manetti F, Botta M. Src inhibitors and angiogenesis. Curr Pharm Design. 2007; 13: 2118-2128.
  • 25
    Shor AC, Kescheman EA, Lee FY, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival. Cancer Res. 2007; 67: 2800-2808.
  • 26
    Sleijfer S, Papai Z, Le Cesne A, et al. Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043. 2007 ASCO Annual Meeting Proceedings, part 1 [abstract]. J Clin Oncol. 2007; 25:( 18S; June 20 suppl). Abstract 10031.
  • 27
    Ansiaux R, Baudelet C, Jordan BF, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res. 2005; 11: 743-750.
  • 28
    McMeekin DS, Sill MW, Darcy KM, et al. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a Gynecological Oncology Group study. Gynecol Oncol. 2007; 106: 596-603.
  • 29
    Boyar MS, Hesdorffer M, Keohan ML, Jin Z, Taub RN. Phase II study of temozolomide and thalidomide in patients with unresectable or metastatic leiomyosarcoma [serial online]. Sarcoma. 2008; 2008: 412503.
  • 30
    Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996; 2: 1843-1849.
  • 31
    Griffon EG, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial pressure in solid tumors. Cancer Res. 1999; 59: 3776-3782.
  • 32
    Penel N, Bui Nguyen B, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 2008; 26: 5269-5274.
  • 33
    Pouyssegur J, Dayan F, Mazur N, et al. Hypoxia signaling in cancer and approaches to enforce tumor regression. Nature. 2006; 441: 437-443.
  • 34
    Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discovery. 2006; 5: 671-688.
  • 35
    Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3: 721-731.
  • 36
    Mita MM, Britten CD, Poplin E, et al. Deforolimus trial 106—a phase I trial evaluating 7 regimens of oral deforolimus (AP23573, MK-8669) [abstract]. J Clin Oncol. 2008; 26( May 20 suppl). Abstract 3509.
  • 37
    Chawla SP, Tolcher AW, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of phase II trial. 2007 ASCO Annual Meeting Proceedings, part 2 [abstract]. J Clin Oncol. 2007; 25( 18S; June 20 suppl). Abstract 10076.
  • 38
    Okuno SH, Mahoney MR, Bailey HH, et al. A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS). 2006 ASCO Annual Meeting Proceedings, part 1 [abstract]. J Clin Oncol. 2006; 24( 18S; June 20 suppl). Abstract 9504.
  • 39
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205-216.
  • 40
    Choi H, Charnsanavej C, Faria S, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25: 1753-1759.
  • 41
    Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007; 25: 1760-1764.